HCV treatment coverage
This indicator measures the rate of initiation of treatment for hepatitis C among people living with HIV on ART diagnosed with chronic HCV infection.
- Hepatitis C is an important co-morbidity in many countries with HIV epidemics.
- Curative treatment for HCV among people living with HIV is an essential means of reducing morbidity and mortality and achieving elimination of HCV.
- Among people living with HIV, people who inject drugs are the most likely to be co-infected with HCV.
Number of people living with HIV on ART diagnosed with chronic viraemic hepatitis C infection (defined as positive HCV antibody (Ab) testing followed by confirmatory testing with either HCV RNA (viral load) or HCV core antigen testing among those HCV Ab-positive) and who initiated HCV treatment during the reporting period
Number of people living with HIV on ART who were diagnosed with chronic viraemic hepatitis C (defined as positive HCV antibody (Ab) testing followed by confirmatory testing with either HCV RNA (viral load) or HCV core antigen testing among those HCV Ab-positive) during the reporting period
For the numerator. Programme records (for example, ART registers, EMRs)
For the denominator. Programme records and/or modelled estimates
Note: All those already diagnosed with HCV and previously treated and cured would be excluded from the denominator.
- People who inject drugs.
WHO Strategic Information Guidelines, 2020 (https://indicatorregistry.unaids.org/sites/default/files/9789240000735-eng.pdf)
10.7 People coinfected with HIV and HCV starting HCV treatment, Global AIDS Monitoring 2020: Indicators for monitoring the 2016 Political Declaration on Ending AIDS (https://www.unaids.org/sites/default/files/media_asset/global-aids-monitoring_en.pdf).